Literature DB >> 1727735

Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine.

D Edelstein1, M Brownlee.   

Abstract

Aminoguanidine-HCl inhibits the formation of advanced glycosylation end products (AGEs) in vitro and in vivo, but the mechanism by which this occurs has not been determined. Aminoguanidine inhibited glucose-derived AGE formation on RNase A by 67-85% at aminoguanidine-glucose molar ratios of 1:5 to 1:50 without affecting the concentration of Amadori products. Fast-atom-bombardment mass spectrometry of RNase peptides incubated with glucose alone or with glucose plus aminoguanidine showed that aminoguanidine inhibited the formation of AGEs without forming an adduct with glycosylated peptide. These data suggest that the primary mechanism of aminoguanidine action is reaction with Amadori-derived fragmentation products in solution. These findings are relevant to the potential clinical use of aminoguanidine in the prevention of diabetic complications.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727735     DOI: 10.2337/diab.41.1.26

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  52 in total

Review 1.  Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy.

Authors:  G Pugliese; F Pricci; G Romeo; G Leto; L Amadio; C Iacobini; U Di Mario
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

Review 2.  [Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus].

Authors:  P P Nawroth; A Bierhaus; G E Vogel; M A Hofmann; M Zumbach; P Wahl; R Ziegler
Journal:  Med Klin (Munich)       Date:  1999-01-15

Review 3.  Advanced glycation: an important pathological event in diabetic and age related ocular disease.

Authors:  A W Stitt
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

Review 4.  Small-molecule inhibition of inflammatory β-cell death.

Authors:  M Lundh; S S Scully; T Mandrup-Poulsen; B K Wagner
Journal:  Diabetes Obes Metab       Date:  2013-09       Impact factor: 6.577

5.  Risk factors for expression and progression of limited joint mobility in insulin-dependent childhood diabetes.

Authors:  J Vuković; M Dumić; A Radica; B Filipović-Grcić; V Jovanović
Journal:  Acta Diabetol       Date:  1996-03       Impact factor: 4.280

6.  Endothelial dysfunction and vascular inflammation in type 2 diabetes: interaction of AGE/RAGE and TNF-alpha signaling.

Authors:  Anna Csiszar; Zoltan Ungvari
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-03       Impact factor: 4.733

7.  Aminoguanidine reduces glomerular inducible nitric oxide synthase (iNOS) and transforming growth factor-beta 1 (TGF-beta1) mRNA expression and diminishes glomerulosclerosis in NZB/W F1 mice.

Authors:  C W Yang; C C Yu; Y C Ko; C C Huang
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

8.  Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock.

Authors:  C C Wu; S J Chen; C Szabó; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

9.  Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature.

Authors:  L Rodríguez-Mañas; J Angulo; S Vallejo; C Peiró; A Sánchez-Ferrer; E Cercas; P López-Dóriga; C F Sánchez-Ferrer
Journal:  Diabetologia       Date:  2003-03-12       Impact factor: 10.122

10.  Inhibition of matrix-induced bone differentiation by advanced glycation end-products in rats.

Authors:  Y Fong; D Edelstein; E A Wang; M Brownlee
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.